Çiğdem Tura Bahadır1, Merve Yılmaz2, Elif Kılıçkan3. 1. Department of Endocrinology and Metabolism, Faculty of Medicine, Amasya University, Amasya, Turkey. 2. Department of Endocrinology and Metabolism, Gazi State Hospital, Samsun, Turkey. 3. Department of Endocrinology and Metabolism, Ondokuz Mayıs University, Samsun, Turkey.
Abstract
BACKGROUND: Thyroid ultrasound, thyroid scintigraphy and radioactive iodine uptake (RAIU) tests are helpful in the differential diagnosis of thyrotoxicosis and hyperthyroidism. In the setting where these techniques are unavailable or unusable more accessible, and cheaper techniques would be helpful. AIMS: We evaluated the capability of free triiodothyronine to free thyroxine ratio (FT3/FT4) to differentiate Graves' Disease (GD) and destructive thyroiditis (DT). METHODS: In total, 318 patients with GD and 140 patients with DT were included in the study. Patients were assigned to two groups: GD and DT (subacute thyroiditis, painless thyroiditis, postpartum thyroiditis). Serum thyroid-stimulating hormone (TSH), FT4, FT3 levels and FT3/FT4 ratio were evaluated in each group. To obtain the optimal diagnostic cut-off value of FT3, FT4 and FT3/FT4 ratio, ROC curve analysis was performed of all untreated thyrotoxicosis patients. RESULTS: The optimal FT3/FT4 ratio cut-off value was 2.96, with a sensitivity of 71.7%, the specificity of 88.6%. The area under the ROC curve of the FT3/FT4 ratio regarding the diagnosis of GD was 0.864 (95% CI: 0.830-0.894). The cut-off level of FT3 for GD was determined as 6.6 pg/mL which had a sensitivity of 72.3% and specificity of 68.6% (AUC = 0.771 P < .001). The cut-off level of FT4 for GD was determined as 3.65 ng/dl with a sensitivity of 35.5% and specificity of 83.6% (AUC = 0.615 P < .001). When a high specificity is needed, FT3/FT4 cut-off value increases to 3.63 with 99.3% specificity and 36.5% sensitivity. CONCLUSIONS: FT3/FT4 ratio helps distinguish GD and DT. In cases of situations where RAIU/scintigraphy and TRAb cannot be studied, the FT3/FT4 ratio is a viable diagnostic tool. Cut-off values with higher specificity can be more helpful in differential diagnosis of GD.
BACKGROUND: Thyroid ultrasound, thyroid scintigraphy and radioactive iodine uptake (RAIU) tests are helpful in the differential diagnosis of thyrotoxicosis and hyperthyroidism. In the setting where these techniques are unavailable or unusable more accessible, and cheaper techniques would be helpful. AIMS: We evaluated the capability of free triiodothyronine to free thyroxine ratio (FT3/FT4) to differentiate Graves' Disease (GD) and destructive thyroiditis (DT). METHODS: In total, 318 patients with GD and 140 patients with DT were included in the study. Patients were assigned to two groups: GD and DT (subacute thyroiditis, painless thyroiditis, postpartum thyroiditis). Serum thyroid-stimulating hormone (TSH), FT4, FT3 levels and FT3/FT4 ratio were evaluated in each group. To obtain the optimal diagnostic cut-off value of FT3, FT4 and FT3/FT4 ratio, ROC curve analysis was performed of all untreated thyrotoxicosispatients. RESULTS: The optimal FT3/FT4 ratio cut-off value was 2.96, with a sensitivity of 71.7%, the specificity of 88.6%. The area under the ROC curve of the FT3/FT4 ratio regarding the diagnosis of GD was 0.864 (95% CI: 0.830-0.894). The cut-off level of FT3 for GD was determined as 6.6 pg/mL which had a sensitivity of 72.3% and specificity of 68.6% (AUC = 0.771 P < .001). The cut-off level of FT4 for GD was determined as 3.65 ng/dl with a sensitivity of 35.5% and specificity of 83.6% (AUC = 0.615 P < .001). When a high specificity is needed, FT3/FT4 cut-off value increases to 3.63 with 99.3% specificity and 36.5% sensitivity. CONCLUSIONS: FT3/FT4 ratio helps distinguish GD and DT. In cases of situations where RAIU/scintigraphy and TRAb cannot be studied, the FT3/FT4 ratio is a viable diagnostic tool. Cut-off values with higher specificity can be more helpful in differential diagnosis of GD.
Authors: Marcio José Concepción Zavaleta; Sofia Pilar Ildefonso Najarro; Esteban Alberto Plasencia Dueñas; María Alejandra Quispe Flores; Diego Martín Moreno Marreros; Luis Alberto Concepción Urteaga; Laura Esther Luna Victorio; Freddy Valdivia Fernández Dávila Journal: Endocrinol Diabetes Metab Case Rep Date: 2021-07-01